ChAdOx1 – Page 13 – Communicable Diseases Research

Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients

면역 억제 환자에서 SARS-CoV-2 백신 접종에 대한 세포 및 체액 반응

Article

Published on 2022-03-012022-09-11
Journal: Cellular immunology [Category] SARS, 치료기술,

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

ChAdOx1 벡터화 백신 AZD2816은 SARS-CoV-2 베타(B.1.351) 및 전임상 연구에서 우려되는 기타 변이체에 대해 강력한 면역원성을 유도합니다.

Article

Published on 2022-03-012022-09-11
Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종,

[키워드] addition animals antibodies AstraZeneca AZD1222 B.1.351 B.1.617.2 Beta binding booster booster dose Booster vaccine booster vaccines caused ChAdOx1 ChAdOx1-vectored vaccine clinical development clinically Course death Delta dose effort expresse funds Gamma hospitalisation Immunity immunogenic increase in induce MRC mutated Mutation nCoV Neutralising Antibodies neutralising antibody new SARS-CoV-2 omicron other variant over P.1 pandemic preclinical study Proteins reduced regimens Research SARS CoV2 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 virus single dose Spike protein Support T cell T cell response T cells the spike protein Vaccine Vaccines variants variants of concern vectored vaccine virus isolate was measured
[DOI] 10.1016/j.ebiom.2022.103902 PMC 바로가기 [Article Type] Article

Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines

COVID-19 백신과 관련된 SARS-CoV-2의 면역 반응에 대한 통찰력

Review

Published on 2022-03-012022-09-11
Journal: Journal of microbiology (Seoul, Korea) [Category] SARS, 변종,

[키워드] Ad26.COV2.S adverse effects antigenic variants applied approved benefit BNT162b2 candidate caused ChAdOx1 ChAdOx1 nCoV-19 clinical setting clinical settings commercialization coronavirus disease Coronavirus disease 2019 COV2.S COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine Effect Health Organization immune immune response immune responses immunological immunologically Inactivated Vaccines insight manifestation Manifestations mRNA mRNA vaccines mRNA-1273 nCoV reported required SARS-CoV-2 Vaccinations Vaccine Vaccine development Vaccines virus infection with COVID-19 World Health Organization
[DOI] 10.1007/s12275-022-1598-x PMC 바로가기 [Article Type] Review

Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy

Research

Published on 2022-02-282022-10-05
Journal: NPJ Vaccines [Category] 임상, 치료기술, 치료법,

[키워드] ACE2 activity age anti-RBD antibody concentration antiretroviral Antiretroviral therapy assessment benefit CD4+ T-cell ChAdOx1 characterized chronic health conditions circulating antibody co-morbidities controls correlation COVID-19 vaccination COVID-19 vaccine domain dose doses Factor Health healthy HIV HIV infection humoral Humoral response immune response initial IQR magnitude median multivariable new SARS-CoV-2 Older age PLWH ranged RBD receiving response second dose significantly Sociodemographic Spike protein the SARS-CoV-2 Treatment vaccination Vaccine vaccine dose vaccine doses variables variant Viral load viral neutralization with HIV
[DOI] 10.1038/s41541-022-00452-6 [Article Type] Research

Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants

알파 및 델타 변이체의 전파에 대한 Covid-19 예방 접종의 영향

Observational Study

Published on 2022-02-242022-09-11
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, 임상, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted Alpha Alpha variant association AZD1222 B.1.1.7 B.1.617.2 BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 Contact coronavirus Ct values declined Delta delta variant Delta variants Department determine Diagnosis Effect England explained greater Lower multivariable nCoV Observational cohort study Patient patients PCR PCR positivity Poisson regression polymerase positive Prevent protection question rate ratio reduced reducing reduction in reductions reductions in retrospective retrospective observational cohort study risk of infection SARS-CoV-2 second vaccination severe acute respiratory syndrome Coronavirus tested Transmission transmission of SARS-CoV-2 vaccination Vaccination Status variant variant call variants Variation Viral load viral loads
[DOI] 10.1056/NEJMoa2116597 PMC 바로가기 [Article Type] Observational Study

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England

Research Article

Published on 2022-02-222022-10-29
Journal: PLoS Medicine [Category] COVID-19, COVID19(2023년), SARS,

[키워드] absolute increase Accuracy adjusted Adults age age and sex analysed Analysis anticoagulant medication antiplatelet Asian association black blood pressure BNT162b2 BNT162b2 vaccines case finding ChAdOx1 ChAdOx1-S coded cohort study confidence interval confounding factors Coronavirus infection covariate covariates COVID-19 COVID-19 mortality COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Deprivation diabetes diagnostic dose DVT Effect effort Electronic health record Electronic health records England estimate estimates event first vaccination Frequency hazard ratio healthcare Hospital admission hospitalisation hospitalised HRs hypertension identify IMPROVE incidence incidence rate increase in increased risk increases in limitation medication morbidity morbidity and mortality Myocardial infarction outcome performed Platelet population level population-based cohort Positive predictive value prevaccination Rate reducing reported researcher residual confounding risk selected Sex smoking stroke therapy threshold thrombosis thrombotic event Thrombotic events vaccination Vaccine Vaccines venous Venous thrombosis white William
[DOI] 10.1371/journal.pmed.1003926 PMC 바로가기 [Article Type] Research Article

First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales

Research Article

Published on 2022-02-222022-10-29
Journal: PLoS Medicine [Category] COVID-19, COVID19(2023년), MERS, SARS,

[키워드] 95% CI 95% confidence interval addition administration Analysis association assumption average baseline benefit Blood BNT162b2 Brain carried Case report case sery caused ChAdOx1 clinically Cohort combined cohort conditions Control count country COVID-19 COVID-19 vaccination dataset datasets dose doses elevated England estimates event events Evidence examined expected extreme first dose Follow-up group Health Health authority incidence rate increased risk independent indication individual information initial limitations Mortality National observation observation period of BNT162b2 Older age outcome outcome measure person year person years Pfizer-BioNTech platform Poisson model primary care Public quantification recorded required researcher risk secondary care Serious Adverse Event Study design thrombosis Topic United Kingdom vaccination Vaccine variable venous Virological with COVID-19
[DOI] 10.1371/journal.pmed.1003927 PMC 바로가기 [Article Type] Research Article

Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa

COVID-19 백신 접종에서 이종 프라임-부스트 전략 채택: 아프리카에서 지역적으로 생성된 증거의 필요성

Article

Published on 2022-02-182022-09-11
Journal: The Pan African Medical Journal [Category] COVID19(2023년), SARS, 변종,

[키워드] access African Alliance approach AstraZeneca booster dose ChAdOx1 ChAdOx1 nCoV-19 clinical trial Coalition country COVAX COVID-19 COVID-19 vaccine COVID-19 vaccines COVID-19-heterologous vaccine database discrimination distribution dose empirical evidence equity Evidence experimental arm generate Heterologous heterologous prime-boost heterologous vaccine immunogenicity in some individual initiative Innovation manuscript Oxford partnership Population prevalence of COVID-19 Prevent prime-boost dose reactogenicity reduced reduction in robust Safety severity vaccination Vaccine variants variants of concern WHO
[DOI] 10.11604/pamj.2022.41.148.31620 PMC 바로가기 [Article Type] Article

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination

Case Report

Published on 2022-02-162022-10-31
Journal: Case Reports in Critical Care [Category] COVID-19,

[키워드] absence Adenovirus arterial carotid carrier caused cerebral venous sinuse ChAdOx1 Clinical course complication of COVID-19 demonstrated described intensive care mRNA receiving stroke thrombosis thrombotic Treatment Vaccine venous
[DOI] 10.1155/2022/6804456 PMC 바로가기 [Article Type] Case Report

Population antibody responses following COVID-19 vaccination in 212,102 individuals

Article

Published on 2022-02-162022-10-04
Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 치료기술, 치료법,